These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 15121602)

  • 1. Anaphylaxis from medroxyprogesterone acetate.
    Selo-Ojeme DO; Tillisi A; Welch CC
    Obstet Gynecol; 2004 May; 103(5 Pt 2):1045-6. PubMed ID: 15121602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New aspects of injectable contraception.
    Phillips OP
    Int J Fertil Womens Med; 2001; 46(1):31-6. PubMed ID: 11294618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depot medroxyprogesterone injectable contraception at the University of Uyo Teaching Hospital, Uyo.
    Abasiattai AM; Udoma EJ; Ukeme E
    Ann Afr Med; 2010; 9(2):81-5. PubMed ID: 20587929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaphylaxis from depot medroxyprogesterone acetate in an adolescent girl.
    Lestishock L; Pariseau C; Rooholamini S; Ammerman S
    Obstet Gynecol; 2011 Aug; 118(2 Pt 2):443-445. PubMed ID: 21768848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous DMPA vs. intramuscular DMPA: a 2-year randomized study of contraceptive efficacy and bone mineral density.
    Kaunitz AM; Darney PD; Ross D; Wolter KD; Speroff L
    Contraception; 2009 Jul; 80(1):7-17. PubMed ID: 19501210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An introductory clinical trial of three-monthly injectable contraceptive-depot medroxyprogesterone acetate].
    Shao Q; Jiang H; Fu W
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jan; 34(1):36-9. PubMed ID: 11263172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine device.
    van Hylckama Vlieg A; Helmerhorst FM; Rosendaal FR
    Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2297-300. PubMed ID: 20798377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary tract infection in the users of depot-medroxyprogesterone acetate.
    Ziaei S; Ninavaei M; Faghihzadeh S
    Acta Obstet Gynecol Scand; 2004 Oct; 83(10):909-11. PubMed ID: 15453884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Depot medroxyprogesterone acetate (DMPA) injectable contraception--safe, effective but neglected method of family planning in Poland].
    Lech MM
    Wiad Lek; 2003; 56(7-8):362-8. PubMed ID: 14969166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Injectable contraception.
    Mishell DR
    J Reprod Med; 2002 Sep; 47(9 Suppl):777-9. PubMed ID: 12380405
    [No Abstract]   [Full Text] [Related]  

  • 11. Depot-medroxyprogesterone acetate: an update.
    Bakry S; Merhi ZO; Scalise TJ; Mahmoud MS; Fadiel A; Naftolin F
    Arch Gynecol Obstet; 2008 Jul; 278(1):1-12. PubMed ID: 18470526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary tract infection in the users of depot-medroxyprogesterone acetate.
    Berger RE
    J Urol; 2005 Sep; 174(3):941. PubMed ID: 16093999
    [No Abstract]   [Full Text] [Related]  

  • 13. Contraceptive efficacy and safety of DMPA-SC.
    Jain J; Jakimiuk AJ; Bode FR; Ross D; Kaunitz AM
    Contraception; 2004 Oct; 70(4):269-75. PubMed ID: 15451329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunosuppressive biological mechanisms support reassessment of use of the injectable contraceptive medroxyprogesterone acetate.
    Hapgood JP
    Endocrinology; 2013 Mar; 154(3):985-8. PubMed ID: 23429710
    [No Abstract]   [Full Text] [Related]  

  • 15. Depot medroxyprogesterone acetate contraceptive injections and skeletal health.
    Renner RM; Edelman AB; Kaunitz AM
    Womens Health (Lond); 2010 May; 6(3):339-42. PubMed ID: 20426597
    [No Abstract]   [Full Text] [Related]  

  • 16. Vaginal discharge: a perceived side effect and minor reason for discontinuation in hormonal injectable users in South Africa.
    Beksinska ME; Rees HV
    Afr J Reprod Health; 2001 Dec; 5(3):84-8. PubMed ID: 12471932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accounting for anovulation and vaginal thinning during depot medroxyprogesterone acetate use.
    Atrio J
    J Infect Dis; 2015 Mar; 211(5):850. PubMed ID: 25217405
    [No Abstract]   [Full Text] [Related]  

  • 18. Hormones and weight change.
    Pelkman C
    J Reprod Med; 2002 Sep; 47(9 Suppl):791-4. PubMed ID: 12380408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous depo-medroxyprogesterone acetate.
    Cameron S
    J Fam Plann Reprod Health Care; 2013 Apr; 39(2):75-7. PubMed ID: 23493590
    [No Abstract]   [Full Text] [Related]  

  • 20. Menstrual pattern and lipid profiles during use of medroxyprogesterone acetate and estradiol cypionate and NET-EN (200 mg) as contraceptive injections.
    Canto de Cetina TE; Luna MO; Cetina Canto JA; Bassol S
    Contraception; 2004 Feb; 69(2):115-9. PubMed ID: 14759615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.